Skip to content

Potential influence of coagulation inhibition on the perception of fear or aggressiveness

Potential influence of coagulation inhibition on the perception of fear or aggressiveness

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00017043
Enrollment
25
Registered
2019-03-28
Start date
2018-11-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48

Interventions

Group 1: Treatment arm: Naturalistic longitudinal examination of approximately 25 adult patients consecutively admitted at one year's hospital admission to the thrombus inhibitor dabigatran (Pradaxa®)
Additionally it is planned: • creation of an ECG
with VHF also LZ-ECG • Blood pressure measurement • 6-minute walk test • Assignment of the patient to a functional performance class (NYHA, EHRA, WHO) • Acquiring echocardiography, if not collected an

Sponsors

Universitätsklinik für Kardiologie und Angiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Treatment group: Patients receiving dabigatran under one of the approved indications, e.g. non-valvular atrial fibrillation, thrombosis, pulmonary embolism or control group: Patients who, after clarifying questionable cardiac arrhythmias, do not require further drug or pacemaker treatment

Exclusion criteria

Exclusion criteria: a) contraindications for dabigatran, e.g. Hypersensitivity to the active substance or to any of the excipients, severe renal insufficiency (creatinine clearance [CrCl] <30 ml / min), acute clinically relevant bleeding, organ damage increasing the risk of bleeding, spontaneous or pharmacological limitation of haemostasis, severe liver disease, concomitant systemically administered ketoconazole, cyclosporin, itraconazole or tacrolimus; Pat. With artificial heart valves. b) Severe infections, trauma, tumors or terminal diseases that affect the brain. c) Lack of consent.

Design outcomes

Primary

MeasureTime frame
- Treatment arm: Change in timidity under anticoagulant therapy: Hamilton anxiety scale / HAM-A - control group: Change in timidity under anticoagulant therapy: Hamilton anxiety scale / HAM-A -exploratory analysis

Secondary

MeasureTime frame
Altering Anxiety with Anticoagulant Therapy: State Trait Anger Expression Inventory / STAXI

Countries

Germany

Contacts

Public ContactOliver Wolfram

Universitätsklinik für Kardiologie und Angiologie

oliver.wolfram@med.ovgu.de+49-391-67-13229

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026